ATI 9242
Alternative Names: ATI-9242Latest Information Update: 15 Dec 2023
Price :
$50 *
At a glance
- Originator ARYx Therapeutics
- Developer ARYx Therapeutics; Braeburn Pharmaceuticals
- Class Antipsychotics
- Mechanism of Action Acetylcholine stimulants; Dopamine release stimulants; GABA modulators; NMDA receptor modulators; Serotonin 7 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Schizophrenia